DrugRisk Advises France May No Longer Furnish Yaz-Type Birth Control Due to Blood Clot Risks

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
YAZ LAWSUIT
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

New York, NY (PRWEB) January 08, 2013

The prescription drug resource center DrugRisk.com has added new information to its already comprehensive database on the birth control drugs Yaz and Yasmin showing French regulatory authorities may no longer reimburse women for the costs of the pills due to increased concerns of health risks.

DrugRisk seeks to improve patient safety through education. This includes furnishing the latest warnings, recalls, studies and litigation news related to prescription drugs like Yaz and Yasmin in both the United States and abroad, explains DrugRisk representative Ryan Mayer.

New information at DrugRisk.com shows France’s Health Ministry last week announced they will no longer reimburse for third and fourth-generation oral contraceptives such as Yaz and Yasmin beginning in March due to concerns over the increased risk of blood clots.* The ANSM also indicated they will study whether limiting prescriptions for such pills to specialists could protect more women.

DrugRisk had previously advised of a new warning by the American College of Obstetricians and Gynecologists that birth control pills containing drospirenone, such as Yaz and Yasmin, may have a higher risk of causing blood clots.**

In legal news, DrugRisk has learned that thousands of Yaz lawsuits have been consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

According to the most recent financial report from Bayer, the company has settled approximately 3,500 of these claims, at a total cost of nearly $750 million, or around $214,000 per case.*** Bayer also confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options. A Yaz lawsuit may be possible to recover damages.

The Drug Risk Resource Center cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

  • reuters.com/article/2013/01/03/france-contraception-idUSL5E9C31XG20130103
**Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
***Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012


Contact